Benlysta class action fails on lack of evidence; Merck KGaA, Bayer arrange new debt financing;

@FiercePharma: Pfizer's targeted lung cancer drug Xalkori too expensive, U.K. cost-effectiveness body says. More | Follow @FiercePharma

@EricPFierce: Teva, Samsung face biosimilar realities. The business is not for the "faint of heart," but has great potential. More | Follow @EricPFierce

> GlaxoSmithKline ($GSK) and Human Genome Sciences won't have to face a class action accusing them of concealing alleged risks of their lupus drug Benlysta, after a judge ruled there wasn't enough evidence that the companies hid suicide reports. Report

> Merck KGaA replaced a €2 billion loan facility with long-term financing. Report

> Bayer priced a $200 million debt issue maturing in 2016. Report

> Children on Medicaid were prescribed antipsychotic drugs 5 times more often than privately-ensured children, a new study found, and many of those prescriptions were for off-label, behavioral uses. Report

> The FDA plans to monitor the Internet to keep a lid on illicit sales of prescription drugs, tobacco and other regulated products. Report

> A Chinese court urged government regulators to better monitor pharmaceutical companies' insurance coverage for compensating patients harmed during clinical trials. Report

> GlaxoSmithKline CEO Andrew Witty touted his company's new Philadelphia-area headquarters in an interview with the Philadelphia Inquirer. Report

Biotech News

 @FierceBiotech: Guest post by Lee Feigenbaum on Big Data sheds light on pharma's 'Small Data' problems. Industry Voices | Follow @FierceBiotech

@JohnCFierce: Blessed by Gates, crowdfunding site funnels cash for high-risk R&D. Report | Follow @JohnCFierce

@RyanMFierce: Aastrom sinks after biotech flushes PhIII study for cardio therapy, halves staff. News | Follow @RyanMFierce

> Sarepta's high-noon decision on eteplirsen draws a big biotech crowd. Story

> Little-known Reviva attracts a big angel crowd for $12M CNS round. More

> What's in a cancer drug name? Maybe a $1.5M cash windfall for researchers. Article

Medical Device News

 @FierceMedDev: Next-gen prostate cancer Dx faces skepticism, competition. Story | Follow @FierceMedDev

 @MarkHFierce: Some companies are shedding drug operations to focus more on devices, while BD is adding a (generic) drug arm. Press release | Follow @MarkHFierce

 @DamianFierce: Intuitive Surgical will have its day in court after a judge ruled to allow a patient's suit. News | Follow @DamianFierce

> As sale rumors abound, Life Tech expands in China. More

> Quidel gains CE mark for herpes/chicken pox molecular Dx. Story

> Becton Dickinson jumps into generic drug business. Article

Drug Delivery News

@MichaelGFierce: FierceDrugDelivery Special Report: Drug-Delivery Device Combos to Watch. Report | Follow @MichaelGFierce

> FDA approves Novartis' inhaled powder drug for cystic fibrosis infection. Story

> Intarcia enrolls PhIII glucose control study for Type 2 diabetes. Item

> Nanoparticles deliver cancer drug, spare fertility. News

> FDA panel OKs Titan's addiction drug delivery platform. More

And Finally... Long-lived Greek islanders may have their boiled coffee to thank, researchers say, though they also eat healthy foods and exercise regularly. Report